The European Commission has approved Novo Nordisk’s new FlexTouch prefilled insulin pen. Approval has been granted for both NovoRapid (insulin aspart) and Levemir (insulin detemir), both modern insulins that are currently delivered in the FlexPen delivery device.
The Danish pharmaceutical firm says FlexTouch, its latest prefilled delivery system, offers a new insulin injection experience for users. Current insulin pens require users to inject their insulin using the force of their thumb to push the button. For some patients this can be difficult. FlexTouch has an easy touch button, which requires very little force to inject the insulin at any dose.
FlexTouch contains 300 units of insulin and doses in one-unit increments, from 1–80 units. It is compatible with NovoTwist needles, which are supplied in 5mm (32G Tip) and 8mm (30G) versions. An audible and tactile ‘click’ confirms attachment of the needle.
The launch of the FlexTouch in the EU is dependent on negotiations in individual countries.
Novo Nordisk gains EU approval for FlexTouch
Danish firm\'s latest innovation within prefilled insulin pens
You may also like
Research & Development
![Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline]()
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline
Read moreThe global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline risk in at-risk older adults during a three-year period
Trending Articles
You may also like
Research & Development
![Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline]()
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline
The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline risk in at-risk older adults during a three-year period
Regulatory
![FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions]()
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions
Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
![Semaglutide patent cliff: pharma industry braces for impact]()
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
